Celltrion Chairman 카지노 바카라 Jung-jin to retain leadership for another two years following re-election approval

[by Ji, Yong Jun] Celltrion Chairman 카지노 바카라 Jung-jin has been reappointed for a two-year term, extended until March 2027.

At the regular shareholders' meeting held on the morning of March 25 at Songdo Convensia in Yeonsu District, Incheon, Celltrion approved the motion to reappoint Chairman 카지노 바카라 Jung-jin as executive director. 카지노 바카라's reappointment was approved by more than half of the voting rights of shareholders present, as well as by over a quarter of the total number of issued shares. The total number of shares represented at the meeting was 124,391,297, accounting for 60.67% of the total issued shares.

카지노 바카라 was unable to attend the shareholders' meeting on this occasion due to personal reasons. "Chairman 카지노 바카라's health recently deteriorated during business activities, and he is currently in recovery after surgery," said 카지노 바카라 Jin-카지노 바카라k, CEO of Celltrion.

카지노 바카라 has demonstrated decisive leadership by addressing major pending issues during his previous term. Notably, he successfully completed the long-awaited merger of Celltrion and Celltrion Healthcare in just nine months following his return. This achievement is seen as laying the groundwork for Celltrion to become a ‘global big pharma’ by acquiring a strong research and development (R&D) foundation and a global sales network.

Additionally, ‘Remsima (infliximab),’ a treatment for autoimmune diseases, surpassed KRW 1 trillion (approximately USD 682.6 million) in global sales last year, becoming Korea’s first ‘global blockbuster treatment.’ Furthermore, ‘Zymfentra (marketed in Europe as Remsima SC),’ a subcutaneous injection (SC) formulation of Remsima, was approved as a ‘novel drug’ by the U.S. Food and Drug Administration (FDA), positioning Celltrion among leading new drug development companies. These accomplishments were achieved during 카지노 바카라’s two-year term.